Literature DB >> 26237167

Reply to 'allogeneic hematopoietic cell transplantation for concurrent multiple myeloma and myelodysplastic syndrome'.

T Schroeder1, R Fenk1, R Haas1, U Germing1, G Kobbe1.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26237167     DOI： 10.1038/bmt.2015.176

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  9 in total

1.  Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia.

Authors:  Oliver Goodyear; Angelo Agathanggelou; Igor Novitzky-Basso; Shamyla Siddique; Tina McSkeane; Gordon Ryan; Paresh Vyas; Jamie Cavenagh; Tanja Stankovic; Paul Moss; Charles Craddock
Journal:  Blood       Date:  2010-06-08       Impact factor: 22.113

2.  Complete remission of Waldenström macroglobulinemia with azacitidine and rituximab.

Authors:  Lukas Weiss; Thomas Melchardt; Daniel Neureiter; Ralf Kemmerling; Sharareh Moshir; Lisa Pleyer; Richard Greil; Alexander Egle
Journal:  J Clin Oncol       Date:  2011-07-05       Impact factor: 44.544

3.  Allogeneic hematopoietic cell transplantation for concurrent multiple myeloma and myelodysplastic syndrome.

Authors:  T Nishihori; R Komrokji; K Shain; C Anasetti
Journal:  Bone Marrow Transplant       Date:  2014-10-20       Impact factor: 5.483

4.  Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS).

Authors:  Sham Mailankody; Ruth M Pfeiffer; Sigurdur Y Kristinsson; Neha Korde; Magnus Bjorkholm; Lynn R Goldin; Ingemar Turesson; Ola Landgren
Journal:  Blood       Date:  2011-07-27       Impact factor: 22.113

5.  Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions--a retrospective multicenter analysis from the German Cooperative Transplant Study Group.

Authors:  Thomas Schroeder; Elena Rachlis; Gesine Bug; Matthias Stelljes; Stefan Klein; Nina Kristin Steckel; Dominik Wolf; Mark Ringhoffer; Akos Czibere; Kathrin Nachtkamp; Ariane Dienst; Mustafa Kondakci; Michael Stadler; Uwe Platzbecker; Lutz Uharek; Thomas Luft; Roland Fenk; Ulrich Germing; Martin Bornhäuser; Nicolaus Kröger; Dietrich W Beelen; Rainer Haas; Guido Kobbe
Journal:  Biol Blood Marrow Transplant       Date:  2014-12-23       Impact factor: 5.742

6.  Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.

Authors:  Antonio Palumbo; Sara Bringhen; Shaji K Kumar; Giulia Lupparelli; Saad Usmani; Anders Waage; Alessandra Larocca; Bronno van der Holt; Pellegrino Musto; Massimo Offidani; Maria T Petrucci; Andrea Evangelista; Sonja Zweegman; Ajay K Nooka; Andrew Spencer; Meletios A Dimopoulos; Roman Hajek; Michele Cavo; Paul Richardson; Sagar Lonial; Giovannino Ciccone; Mario Boccadoro; Kenneth Anderson; Bart Barlogie; Pieter Sonneveld; Philip L McCarthy
Journal:  Lancet Oncol       Date:  2014-02-11       Impact factor: 41.316

7.  Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation.

Authors:  T Schroeder; A Czibere; U Platzbecker; G Bug; L Uharek; T Luft; A Giagounidis; F Zohren; I Bruns; C Wolschke; K Rieger; R Fenk; U Germing; R Haas; N Kröger; G Kobbe
Journal:  Leukemia       Date:  2013-01-14       Impact factor: 11.528

Review 8.  Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives.

Authors:  R Zeiser; H Bertz; A Spyridonidis; L Houet; J Finke
Journal:  Bone Marrow Transplant       Date:  2004-12       Impact factor: 5.483

9.  Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and concurrent lymphoid malignancy.

Authors:  Z Zimmerman; B L Scott; A K Gopal; B M Sandmaier; D G Maloney; H J Deeg
Journal:  Bone Marrow Transplant       Date:  2011-09-12       Impact factor: 5.483
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.